Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicillamine.
A new antimetabolite approach to block the replication of the AIDS (acquired immunodeficiency syndrome)-associated virus is described. In this communication the effect of a synthetic D-penicillamine (Trolovol) and L-penicillamine on the replication of HTLV-III/LAV was studied. The replication of HTLV-III/LAV in H9 cells was determined by measuring the expression of HTLV-III proteins p15 and p24 using monoclonal antibodies in an immunofluorescence assay system. A concentration dependent inhibition of HTLV-III replication by D- and L-penicillamine was observed. At lower concentrations L-penicillamine was more effective than D-penicillamine. However, at concentrations above 20 micrograms/ml the inhibitory response of both isomers is similar. To obtain a total inhibition a drug concentration of 40 micrograms/ml was needed for both isomers. Cytotoxicity of the compounds in uninfected H9 cells was observed only at high concentrations; e.g., at 500 micrograms/ml a 32% inhibition was found for D-penicillamine and a 24% inhibition for L-penicillamine. In the presence of D- or L-penicillamine there was a significant increase in cell density of infected H9 cell cultures, indicating that both the compounds have a protective effect on H9 cells. In view of the low cytotoxicity, a selective antiviral activity against HTLV-III/LAV, and a T-cell protective effect of D-penicillamine, the evaluation of D-penicillamine for clinical treatment of AIDS is implicated.
D000911:Antibodies, Monoclonal / Q000032:analysis; D002478:Cells, Cultured; D017977:Deltaretrovirus / Q000187:drug effects* / Q000502:physiology; D003864:Depression, Chemical; D005455:Fluorescent Antibody Technique; D006801:Humans; D010396:Penicillamine / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D010396:Penicillamine